BR112022001336A2 - Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo - Google Patents

Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo

Info

Publication number
BR112022001336A2
BR112022001336A2 BR112022001336A BR112022001336A BR112022001336A2 BR 112022001336 A2 BR112022001336 A2 BR 112022001336A2 BR 112022001336 A BR112022001336 A BR 112022001336A BR 112022001336 A BR112022001336 A BR 112022001336A BR 112022001336 A2 BR112022001336 A2 BR 112022001336A2
Authority
BR
Brazil
Prior art keywords
her2
antibody
bispecific
bispecific anti
cancer
Prior art date
Application number
BR112022001336A
Other languages
English (en)
Other versions
BR112022001336A8 (pt
Inventor
Chanmoo Lee
Donghoon Yeom
Eun-Jung Lee
Eunjung Kim
Eunyoung Park
Hyejin Chung
Junghyeon Hong
Kyeongsu Park
Young Song Moo
Rae Lee Na
Seawon Ahn
Taewang Kim
Ui-Jung Jung
Wonjun Son
Yangsoon Lee
Yeryoung Yong
Yong-Gyu Son
Bong Park Young
Original Assignee
Abl Bio Inc
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abl Bio Inc, Yuhan Corp filed Critical Abl Bio Inc
Publication of BR112022001336A2 publication Critical patent/BR112022001336A2/pt
Publication of BR112022001336A8 publication Critical patent/BR112022001336A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo. são fornecidos um anticorpo biespecífico anti-4-1bb/anti-her2 e uma composição farmacêutica e um método para tratar e/ou prevenir um câncer usando o mesmo.
BR112022001336A 2019-07-26 2020-07-27 Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo BR112022001336A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962878951P 2019-07-26 2019-07-26
US202063024608P 2020-05-14 2020-05-14
PCT/KR2020/009871 WO2021020846A1 (en) 2019-07-26 2020-07-27 Anti-her2/anti-4-1bb bispecific antibody and use thereof

Publications (2)

Publication Number Publication Date
BR112022001336A2 true BR112022001336A2 (pt) 2022-03-22
BR112022001336A8 BR112022001336A8 (pt) 2023-02-07

Family

ID=74190718

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022001336A BR112022001336A8 (pt) 2019-07-26 2020-07-27 Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo

Country Status (11)

Country Link
US (1) US20210024650A1 (pt)
EP (1) EP4004054A4 (pt)
JP (1) JP2022542574A (pt)
KR (1) KR20220038768A (pt)
CN (1) CN114206941A (pt)
AU (1) AU2020320233A1 (pt)
BR (1) BR112022001336A8 (pt)
CA (1) CA3147423A1 (pt)
MX (1) MX2022001022A (pt)
WO (1) WO2021020846A1 (pt)
ZA (1) ZA202200906B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115151573A (zh) * 2020-02-28 2022-10-04 上海复宏汉霖生物技术股份有限公司 抗cd137构建体、多特异性抗体及其用途
KR20230042524A (ko) * 2020-08-07 2023-03-28 주식회사 유틸렉스 항-her2 / 항-4-1bb 이중특이적 항체 및 이의 용도
WO2023195810A1 (en) * 2022-04-07 2023-10-12 Yuhan Corporation Pharmaceutical composition for treating or preventing cancer with low expression level of her2

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012145183A2 (en) * 2011-04-19 2012-10-26 Pfizer Inc. Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
WO2016149665A1 (en) * 2015-03-18 2016-09-22 Baylor College Of Medicine Her2/erbb2 chimeric antigen receptor
AU2016258977C1 (en) * 2015-05-04 2022-07-14 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
WO2016205176A1 (en) * 2015-06-15 2016-12-22 Genentech, Inc. Antibodies and immunoconjugates
SG11201808196UA (en) * 2016-03-31 2018-10-30 Neon Therapeutics Inc Neoantigens and methods of their use
KR102426765B1 (ko) * 2016-04-22 2022-07-29 엘리게이터 바이오사이언스 에이비 Cd137에 대한 신규한 이중특이성 폴리펩타이드
MX2019005029A (es) * 2016-11-03 2019-10-24 Juno Therapeutics Inc Terapia de combinación de una terapia de células t y un inhibidor de tirosina cinasa de bruton (btk).
AU2018224094A1 (en) * 2017-02-24 2019-09-19 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
WO2019016402A1 (en) * 2017-07-20 2019-01-24 Aptevo Research And Development Llc BINDING PROTEINS BINDING AT 5T4 AND 4-1BB, COMPOSITIONS AND METHODS RELATED THERETO
US20220056136A1 (en) * 2018-11-30 2022-02-24 Abl Bio Inc. Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof

Also Published As

Publication number Publication date
CN114206941A (zh) 2022-03-18
ZA202200906B (en) 2023-11-29
BR112022001336A8 (pt) 2023-02-07
CA3147423A1 (en) 2021-02-04
KR20220038768A (ko) 2022-03-29
EP4004054A1 (en) 2022-06-01
AU2020320233A1 (en) 2022-02-17
US20210024650A1 (en) 2021-01-28
JP2022542574A (ja) 2022-10-05
MX2022001022A (es) 2022-04-18
WO2021020846A1 (en) 2021-02-04
EP4004054A4 (en) 2023-10-25
AU2020320233A8 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
BR112022001336A2 (pt) Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo
CL2019001740A1 (es) Novedoso conjugado de amanitina.
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
CL2018003407A1 (es) Anticuerdos anti-pd-1, método para producir el mismo y método para usar el mismo.
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
BR112017006468A2 (pt) anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer
JOP20180021A1 (ar) الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
WO2020082209A8 (zh) 抗cldn18.2抗体及其用途
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
ZA202206885B (en) Anti-pd-1-anti-vegfa bispecific antibody, pharmaceutical composition and use thereof
BR112022008365A2 (pt) Inibidores de cd73
BR112022012731A2 (pt) Anticorpo anti-ox40 e uso do mesmo
BR112022004972A2 (pt) Anticorpos, ácidos nucleicos isolados, células hospedeiras isoladas, métodos de produção de um anticorpo, de produção de um anticorpo biespecífico e de tratamento de um indivíduo, anticorpos biespecíficos, composição farmacêutica, anticorpo, anticorpo biespecífico ou composição farmacêutica, combinação de um anticorpo, uso do anticorpo, uso de uma combinação do anticorpo e métodos para reduzir a inflamação e para melhorar a descamação e/ou de erupção cutânea e combinação para uso
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
EA202192146A1 (ru) Антитела к клаудину 6 и их применение
BR112022012867A2 (pt) Tratamento de câncer com inibidores de cdk12/13
CL2021001739A1 (es) Inhibidores de la proteína de activación de fibroblastos.
BR112022001329A2 (pt) Anticorpo biespecífico anti-egfr/anti-4-1bb e uso do mesmo
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
ECSP21044421A (es) Anticuerpos anti-pmel17 y conjugados de los mismos
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
PH12020552159A1 (en) Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: YUHAN CORPORATION (KR)